INSERM U895, Mediterranean Center of Molecular Medicine (C3M), Team 7 Molecular and Cellular Physiopathology of Obesity and Diabetes, Nice, France.
Curr Opin Pharmacol. 2009 Dec;9(6):753-62. doi: 10.1016/j.coph.2009.07.004. Epub 2009 Aug 13.
Insulin receptor substrates (IRS) serine phosphorylation is a time-controlled physiological feedback mechanism in insulin signaling that is hijacked by metabolic and inflammatory stresses to promote insulin resistance. Kinases, including IKKbeta, JNK, ERK, mTOR, and S6K, activated by the inducers of insulin resistance induce uncontrolled IRS serine phosphorylation. Studies with genetically modified mice reveal that these kinases integrate signals from metabolic and inflammatory stresses in adipose tissue, liver, and hypothalamus leading to peripheral and central insulin resistance. Moreover, IKKbeta/NF-kappaB and JNK1 pathways in myeloid cells represent a core mechanism involved in inflammation linked to obesity. These kinases are thus potential drug targets against insulin resistance and the targeting of the IKKbeta/NF-kappaB or the JNK pathway may evolve into future diabetes medication.
胰岛素受体底物 (IRS) 丝氨酸磷酸化是胰岛素信号转导中的一种受时控的生理反馈机制,它被代谢和炎症应激劫持,以促进胰岛素抵抗。由胰岛素抵抗诱导剂激活的激酶,包括 IKKβ、JNK、ERK、mTOR 和 S6K,会引起不受控制的 IRS 丝氨酸磷酸化。利用基因修饰小鼠进行的研究表明,这些激酶整合了来自脂肪组织、肝脏和下丘脑的代谢和炎症应激信号,导致外周和中枢胰岛素抵抗。此外,髓样细胞中的 IKKβ/NF-κB 和 JNK1 途径是与肥胖相关的炎症的核心机制之一。因此,这些激酶是针对胰岛素抵抗的潜在药物靶点,针对 IKKβ/NF-κB 或 JNK 途径的靶向治疗可能会发展成为未来的糖尿病药物。